The FDA Announces a Recall of This Children's Cough Syrup Dating Back to 2022
The US Food and Drug Administration announced Wednesday that Medtech Products has voluntarily recalled five lots of Little Remedies Honey Cough Syrup, a 100% natural kid's cough medicine for ages 1 year and up. The cough syrup was found to contain Bacillus cereus, a bacterium that can cause two types of food-borne illnesses, and has lost its shelf-stability.
The five affected lots were distributed in the US both online and in retail stores from Dec. 14, 2022, to June 4, 2025. The lot numbers are 0039, 0545, 0640, 0450 and 1198, while the affected expiration dates extend to December 2026.
The FDA reports that "no serious adverse events have been reported to date."
This cough syrup contains three ingredients: honey, purified water and a natural preservative.
Amazon
If you purchased a Little Remedies Honey Cough Syrup that has been recalled, stop using it immediately. If your child has experienced any issues that may be related to this product, contact their doctor. For reimbursement, you can email Medtech at medicalaffairs@prestigebrands.com, contact via its website at or by phone at (800) 754-8853, Monday through Friday from 8:30 a.m. to 5:30 p.m. Eastern time.
Any reactions or quality issues can be reported to the FDA's MedWatch Adverse Event Reporting program.
What is Bacillus cereus?
The FDA reports that Bacillus cereus or B. cereus is a bacterium that can cause two types of foodborne illnesses.
The first type can start 1 to 6 hours after consumption of the contaminated food or drink. Symptoms include: stomach cramps, vomiting and nausea.
The second type of foodborne illness that Bacillus cereus causes can occur 8 to 16 hours after consumption. Its symptoms are diarrhea and stomach cramps.
"Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death," the FDA said.
If your child is demonstrating any of these symptoms related to the consumption of Little Remedies Honey Cough Syrup, contact their doctor immediately.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
31 minutes ago
- CBS News
San Francisco mayor announces pilot program for firefighters to get cancer screening tests
San Francisco's firefighters could get cancer screening tests through a proposed city initiative, Mayor Daniel Lurie announced Tuesday. The initiative would give active-duty firefighters over the age of 40 with at least five years of service access to image scans and screenings, the city said. "You are the protectors of our city, and now, we're here to protect you," Lurie said. "I'm proud to announce this investment for cancer screenings for firefighters across San Francisco. We know screenings save lives—when we catch cancer early, it drastically increases the survival rate of our firefighters. This investment is about honoring the people who dedicate their lives to protecting ours." Lurie said his proposed budget includes a $500,000 investment for the program, and that it would be led by the city's fire department. The initiative is modeled after the San Francisco Firefighter Cancer Prevention Foundation's program. "The SFFCPF program this pilot program will be modeled after demonstrated high participation and effective early detection, identifying cancers that might have otherwise gone undiagnosed until more advanced stages," the city said. According to the city's press release, Lurie would use private contributions to fully fund the program and ensure it continues to operate. The mayor's office said Lurie is currently working with the Board of Supervisors on legislation to allow him to raise that money. The mayor's office said the International Association of Fire Fighters Local 798, the SFCPF, and the Fire Department will be helping design the pilot before its launch.
Yahoo
39 minutes ago
- Yahoo
Why This Beaten Down Biotech Stock Might Be a Hidden Gem
In the volatile biotech industry, it is easy to overlook small-cap medical device companies, particularly those that are not yet profitable. But every now and then, a company slips under the radar despite having the ideal combination of innovation, market opportunity, and long-term strategic execution. One such company is Alphatec Holdings (ATEC), a medical technology firm specializing in advanced spine surgery solutions. Alphatec uses artificial intelligence (AI) technologies to improve surgical precision, automate signal monitoring, and provide intraoperative analytics. While it is not a pure-play AI company, AI is becoming more integrated into its platform, helping to shape the future of spine surgery. Dear Tesla Stock Fans, Mark Your Calendars for June 22 Nvidia Says Quantum Computing Is Nearing an 'Inflection Point.' Here Are the 3 Best Stocks to Buy Now to Profit. Warren Buffett Loves This Cheap Dividend Stock and So Do Company Insiders Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. With consistent revenue growth, ATEC is gradually gaining traction. Valued at a market capitalization of $1.6 billion, Alphatec stock has risen 21% year to date (YTD), outperforming the S&P 500 Index's ($SPX) gain of 2.2% YTD. Long-term investors who are willing to dig deeper may find this beaten-down growth stock to be a hidden gem. Founded in 1990, Alphatec initially focused on spinal implants and surgical instrumentation. However, it is now reimagining spine surgery as a fully integrated experience, with cutting-edge implants, navigation systems, and surgical software. The company's platform is intended to assist spine surgeons in operating with greater precision, reducing complications, shortening patient recovery times, and collecting intraoperative data for better long-term outcomes. Alphatec has achieved double-digit revenue growth lately, owing to increased surgeon adoption and new product launches. In the first quarter of 2025, total revenue increased 22% year on year to $169 million, with surgical revenue up 24%. Procedure volume is increasing as more surgeons use Alphatec's approaches. The company is quickly becoming a preferred partner for spine surgeons because of its technological capabilities. In Q1, Alphatec experienced an 18% increase in new surgeon adoption. Like most growth companies, Alphatec has yet to turn a profit despite increasing revenues. These losses are largely the result of aggressive reinvestment in growth, research and development (R&D), and surgeon support. During the quarter, the company spent $16.58 million on R&D. Adjusted gross margin reached 70.4% in the quarter. Looking at the firm's consistent revenue growth and margins, profitability may not be far away, especially if the company continues to increase procedure volumes and expand its ecosystem. Adjusted EBITDA stood at $10.5 million in the quarter, up from a $3 million loss in the year-ago quarter. At the end of Q1, Alphatec had $153.2 million in cash and cash equivalents. Management expects adjusted EBITDA of $78 million in 2025, compared to $31 million in the previous year. Analysts covering Alphatec predict that revenue will increase by 20.1% in 2025, in line with management's expectations. Revenue could rise by 18.3% in 2026, with losses gradually declining. The U.S. spine surgery market is large and growing, with a projected value of $20 billion by 2031. Chronic back pain and spinal deformities are on the rise, owing to the aging population and climbing obesity rates. While Alphatec's market share remains small, this allows the company plenty of room to grow. As demand for more precise and less invasive surgeries increases, the few companies like Alphatec with integrated, AI-capable surgical platforms may lead their industry. Of course, growing biotech stocks can be risky. Alphatec faces stiff competition from larger, established players in the medical technology industry, such as Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT). Furthermore, continued losses may necessitate additional capital raises or risk share dilution. For a company in its early growth stages, however, these risks are manageable, especially given Alphatec's strong traction with both products and customers. Its sole focus on spine surgery also distinguishes the firm as an expert in its field, which is also known as a moat. Still, because Alphatec is a growing biotech company, ATEC is better suited for aggressive investors willing to hold the stock until it reaches its full potential. Last month, H.C. Wainwright analyst Sean Lee reiterated his 'Buy' rating on ATEC stock, citing the company's strong Q1 2025 performance and growth trajectory. Lee emphasized Alphatec's improved profitability, citing consecutive quarters of positive adjusted EBITDA and a decrease in cash burn. The company now expects positive cash flow by year-end, with a projected increase in adjusted EBITDA for 2025. Despite regulatory and financial risks, Lee believes Alphatec is well-positioned for long-term growth. Backed by valuation metrics like EV-to-sales and DCF analysis, Lee set a 12-month price target of $20 per share. Separately, Barclays also maintained a 'Buy' rating on ATEC with a price target of $21. Recently, Lake Street initiated coverage of ATEC stock with a price target of $18 and a 'Buy' rating. According to the analyst, Alphatec is the only major spine company fully committed to improving spinal surgery outcomes, while the rest of the industry appears disorganized or uncertain. Lake Street also predicts that Alphatec's exceptional growth rate will continue. On Wall Street, ATEC is rated a 'Strong Buy' by consensus. Of the 11 analysts covering the stock, nine have rated it a 'Strong Buy' while one analyst recommends a 'Moderate Buy' rating and one rates the stock a 'Hold.' Based on its mean price target of $18.32, Wall Street expects the stock to climb as high as 66% from current levels. Furthermore, the Street-high estimate of $22.50 per share implies potential upside of nearly 105% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
US to end LGBT suicide prevention service, says general hotline sufficient
(Clarifies in second paragraph that funding was not renewed from earlier mention of fund being pulled) By Kanishka Singh WASHINGTON (Reuters) -U.S. President Donald Trump's administration is ending funding for an LGBT suicide prevention hotline that it says encourages "radical gender ideology," a move that the project running the service called "devastating." The Trevor Project, a non-profit that provides free, specialized support to LGBT youth, said on Wednesday that its hotline would soon close as a result of the funding not being renewed. "I am devastated and heartbroken. The @TrevorProject received official notice that The Trump administration has ordered the closure of the national LGBTQ+ youth suicide lifeline in 30 days," Trevor Project CEO Jaymes Black said in a statement on Instagram. A spokesman for the White House Office of Management and Budget said funding would continue for 988 Lifeline, a wider suicide prevention hotline. "The president's Budget funds the 988 at $520 million – the same number as under (former President Joe) Biden. It does not, however, grant taxpayer money to a chat service where children are encouraged to embrace radical gender ideology by 'counselors' without consent or knowledge of their parents," the spokesman added. Since taking office in January, Trump has signed multiple executive orders aimed at restricting transgender rights and dismantling diversity, equity and inclusion practices in the government and private sector. The Trump administration says such steps restore fairness, but civil rights and LGBT advocates say they leave marginalized groups more vulnerable. "The administration is eliminating a critical, life-saving resource that was part of this nation's public health infrastructure," said Black, adding that it seemed the country "has failed our LGBTQ+ young people." The hotline had serviced over 1.3 million young people since its inception in 2022, Black added.
